Headquartered in Cambridge, MA Fiscal year ends December NASDAQ: BIIB biogen.com
Biogen Inc. is a biotechnology company that develops and delivers therapies for people living with serious neurological, rare, and autoimmune diseases. Its product portfolio spans multiple sclerosis (TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI), rare disease (SPINRAZA for spinal muscular atrophy, SKYCLARYS for Friedreich's ataxia, QALSODY for ALS), specialized immunology (SYFOVRE for geographic atrophy, EMPAVELI for complement-mediated diseases — both acquired through the 2026 Apellis acquisition), and neuropsychiatry (ZURZUVAE for postpartum depression). Biogen also generates revenue from anti-CD20 therapeutic programs including royalties on OCREVUS and profit-sharing on RITUXAN, GAZYVA, and LUNSUMIO, as well as from its Alzheimer's collaboration with Eisai on LEQEMBI. The company operates a biosimilars business through its collaboration with Samsung Bioepis, marketing products including BENEPALI, IMRALDI, and FLIXABI. Biogen's pipeline includes litifilimab (anti-BDCA2 for lupus), felzartamab (anti-CD38 for antibody-mediated rejection), zorevunersen (for Dravet syndrome), and salanersen, with multiple Phase 3 readouts expected through 2027. Updated
Biogen's growth portfolio, boosted by the first full quarter of Apellis products, rose 49% year over year to $1.26 billion and finally outran the shrinking MS franchise. Management raised the low end of full-year non-GAAP EPS guidance, and the first Phase 3 litifilimab data lands in December.
A House Foreign Affairs member just unwound much of a portfolio in one sweep: 42 trades across tech, defense, banks and pharma, most of them sales dated September 24, disclosed 35 days later. The largest line is a Snowflake purchase of $15,001 to $50,000 made earlier that month, matched against an equally sized Cisco exit.
Hern sold across 28 equity positions in August, from Adobe and Boeing to Microsoft and Home Depot, and put $100K to $250K into an Oklahoma municipal bond instead. That is a wholesale rotation out of stocks and into tax-free paper by a Ways and Means member now running for Senate, disclosed 27 days later.
Pre-Market Stock Futures: Futures are trading mixed as we head into a week that marks the start of third-quarter earnings reports, with big-money banks leading off tomorrow. All major indices finished higher…
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across the RNA and rare-disease biotech space with…
Biogen (NASDAQ:BIIB | BIIB Price Prediction) picked up a strong endorsement from Wall Street on Wednesday, as UBS analyst Michael Yee upgraded the stock to Buy from Neutral and raised his price…
David Moadel Pre-Market Stock Futures: Futures are trading higher as we hit the midweek point. All major indices finished lower on Tuesday as the deadline for the ceasefire approached, amid threats to cancel talks…
Biogen (NASDAQ:BIIB | BIIB Price Prediction) stock just earned a strong endorsement from Wells Fargo on Monday, as analyst Mohit Bansal upgraded the shares to Overweight from Equal Weight and raised his…
David Moadel Pre-Market Stock Futures: The futures are trading mixed this morning, after what started as another week of the same old song and dance yesterday, before stocks turned around before noon, and it…
Josh Brown, CEO of Ritholtz Wealth Management, made a pointed claim on CNBC’s Halftime Report this week about large-cap biotech: “These are growth stocks where you don’t have to worry about disruption.…
Pre-Market Stock Futures: Futures are trading modestly lower as the big day has finally arrived: the Federal Reserve will wrap up its last meeting of 2025, and the odds still heavily favor…
Pre-Market Futures: The futures are trading modestly higher on Thursday after a big snap-back rally on Wednesday, as all the major indices staged a solid rebound following the Tuesday sell-off. While some…
If you work in the biotech industry, you might know the name Alex Denner. If not, his name probably doesn’t ring a bell. Denner is the CEO and CIO of Sarissa Capital…
Markets are tanking on tariff fears, inflationary concerns and now fears of recession. “Given this is so uncertain and that there are new announcements every hour or so, it’s kind of unclear…
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Viking Therapeutics.
Billionaire investor Ken Griffin is the founder of Citadel Advisors, one of the world’s most successful alternative investment firms. With over $96 billion in assets under management (AUM), Griffin’s hedge fund is…
Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their shares into smaller slices. Walmart (NYSE:WMT | WMT Price Prediction)…
Dementia is a major healthcare problem across the globe. It is estimated by medical professionals that someone develops some form of dementia every three seconds, and about 55-60 million people currently suffer…
Biogen Inc. is a biotechnology company that develops and delivers therapies for people living with serious neurological, rare, and autoimmune diseases.
24/7 Wall St.'s 12-month price target for BIIB is $299.12, rated Buy. The Wall Street consensus target is $247.32. BIIB price prediction →
